Skip to main content
Bayer AG logo

Bayer AG — Investor Relations & Filings

Ticker · BAY ISIN · DE000BAY0017 LEI · 549300J4U55H3WP1XT59 F Manufacturing
Open in API
Filings indexed 365 across all filing types
Latest filing 2023-12-08 Regulatory Filings
Country DE Germany
Listing F BAY

About Bayer AG

https://www.bayer.com/en/

Bayer AG is a global life science company with core competencies in the fields of healthcare and nutrition. Guided by its mission "Health for all, Hunger for none," the company develops products and services to address fundamental human needs and global challenges. Its operations are divided into three main divisions: Pharmaceuticals, which focuses on prescription products; Consumer Health, which offers over-the-counter medications and supplements; and Crop Science, which provides tailored solutions for farmers including seeds, crop protection, and digital farming technologies. Bayer's activities encompass the discovery, development, manufacturing, and commercialization of its product portfolio, aiming to improve quality of life and ensure a sustainable supply of food and feed.

Recent filings

Filing Released Lang Actions
§§ 264 Abs. 3, 264b HGB zum Geschäftsjahr vom 01.01.2023 bis zum 31.12.2023
Regulatory Filings Classification · 92% confidence The document is a formal announcement ('Bekanntmachung') from Bayer Aktiengesellschaft concerning the fiscal year 2023 (01.01.2023 to 31.12.2023). It specifically references German commercial code sections (§§ 264 Abs. 3, 264b HGB) related to the exemption from full disclosure requirements for subsidiaries included in a consolidated group statement. This type of filing, which deals with specific accounting treatments, consolidation, and regulatory compliance under national law (HGB), is not explicitly covered by the standard SEC forms (10-K, IR, ER). Given the context of financial reporting compliance and the specific nature of the disclosure regarding consolidation and exemptions, it is most closely related to formal financial reporting or regulatory compliance documentation. Since it is not a full Annual Report (10-K), an Interim Report (IR), or a standard Audit Report (AR), and it is a specific regulatory disclosure, it fits best under the general 'Regulatory Filings' (RNS) category as a miscellaneous, legally mandated disclosure that doesn't fit the other specific financial report types. The document length is short (1370 chars), but it is the primary document, not an announcement of another document, so RPA is less appropriate than RNS for this specific regulatory notice.
2023-12-08 German
Ad-hoc-Meldung gemäß Art. 17 MAR in Verbindung mit § 4 Abs. 1 S. 1 Nr. 1a WpAV
Regulatory Filings Classification · 98% confidence The document is explicitly labeled as an 'Ad-hoc-Meldung gemäß Art. 17 MAR' (Ad-hoc announcement according to Article 17 MAR) and contains 'Disclosure of an inside information'. This type of immediate, material disclosure regarding company events (in this case, stopping a clinical study due to lack of efficacy) is a mandatory regulatory announcement. Since it is a specific, time-sensitive regulatory disclosure that doesn't fit the detailed definitions of 10-K, ER, or IR, the most appropriate general category for mandatory regulatory announcements that don't fit elsewhere is 'Regulatory Filings' (RNS). It is not a presentation (IP/AGM-R), a full report (10-K/IR), or a management discussion (MDA).
2023-11-19 English
Q3 statement / Q3 financial report 2023
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Statement' for the third quarter of 2023 for the Bayer Group. It contains detailed financial tables, including sales, EBITDA, EBIT, net income, and cash flow data, as well as management commentary on performance and key events. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). Q3 2023
2023-11-08 English
Halbjahresfinanzbericht nach WpHG zum Geschäftsjahr vom 01.01.2023 bis zum 30.06.2023
Interim / Quarterly Report Classification · 100% confidence The document is a 'Halbjahresfinanzbericht' (Half-Year Financial Report) for Bayer AG for the period ending June 30, 2023. It contains comprehensive financial statements, including income statements, cash flow data, and detailed management analysis of financial performance (EBITDA, EBIT, revenue, etc.). As it covers a period shorter than a full fiscal year and provides substantive financial data, it is classified as an Interim/Quarterly Report. H1 2023
2023-08-08 German
Half-yearly financial report 2023
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Half-Year Financial Report 2023' and contains comprehensive financial statements, including consolidated income statements, statements of financial position, and cash flows for the period ending June 30, 2023. It also includes an 'Interim Group Management Report'. This fits the definition of an Interim/Quarterly Report (IR) as it provides substantive financial data and analysis for a period shorter than a full fiscal year. H1 2023
2023-08-08 English
Q1 statement / Q1 financial report 2023
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Statement' for the first quarter of 2023, containing detailed financial tables (Group sales, EBITDA, EBIT, Net income, etc.), management commentary on performance, and key events. It provides substantive financial data and analysis for a period shorter than a full fiscal year, which fits the definition of an Interim/Quarterly Report (IR). It is not a mere announcement (RPA) as it contains the actual financial results and analysis. Q1 2023
2023-05-11 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.